IMAGINE
VIRTUAL KOL EVENT
The Potential Role of Anti-OX40/OX40L Monoclonal Antibodies (mAbs) in the Treatment of Alopecia Areata (AA)
Wednesday, May 28th, 2025 | 11:00AM ET
AT INMAGENE
We are pioneering a new generation of therapies with best-in-class potential across a spectrum of immunological and inflammatory diseases. Leveraging external innovation and our proprietary QuadraTek® platform, we are developing differentiated treatments that have the potential to offer better outcomes to patients.
Our science
Our lead candidates have been engineered to address a broad spectrum of immune and inflammatory indications while optimizing safety, efficacy, and convenience.
Pipeline
We are developing a new generation of therapies for patients living with immunologic and inflammatory diseases.
Partnerships
Join our mission to deliver better therapies to patients in need.
News
Explore our most recent updates.